CTXR

Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Citius Pharmaceuticals, Inc. (CTXR) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) B+ (3.7) B (3.2) D+ (1.7) C+ (2.6) B- (2.9)
2026-11-04 B- (3.0) B+ (3.7) B (3.2) D+ (1.8) C+ (2.7) B- (2.9)
2026-10-28 B- (3.0) B+ (3.7) B (3.2) C- (2.1) C+ (2.7) B- (2.9)
2026-10-21 B- (3.0) B+ (3.7) B (3.2) D+ (1.6) C+ (2.6) C+ (2.8)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe